Daily GLP-1 tablets are reshaping the fast-growing market for obesity treatments.
The new oral Wegovy from Novo Nordisk has drawn strong early demand in the US and could bring these drugs to a wider group of patients.
Analysts believe easier dosing, lower prices and no need for refrigeration will make pills more mainstream than injections.
Many users are switching from weekly shots such as Zepbound because insurance coverage and costs have changed.
Patients report steadier appetite control and simpler routines, though some still prefer a weekly injection to a daily dose.
Rival Eli Lilly is preparing its own tablet, orforglipron, intensifying a race that could define the sector’s next phase.
While pills are less effective for major weight loss, they are expected to attract people who are overweight rather than severely obese.
With global obesity rising and more insurance programmes starting to pay for treatment, drugmakers see huge potential.
Forecasts suggest the GLP-1 market could approach $200bn within the next decade.
